Caricamento...
Predictors of Ustekinumab Failure in Crohn’s Disease After Dose Intensification
BACKGROUND: Many patients with Crohn’s disease (CD) who lose response to the standard ustekinumab dose interval of every 8 weeks (q8w) undergo dose intensification to q4w or q6w. However, baseline factors that predict success or failure after dose intensification are unknown. We sought to identify p...
Salvato in:
| Pubblicato in: | Inflamm Bowel Dis |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8314105/ https://ncbi.nlm.nih.gov/pubmed/33146703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izaa282 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|